Iovance Biotherapeutics $IOVA rose 20.61% today.


The consensus target price for the stock among analysts remains at $8.43/$8.80.
The company's market capitalization is considered quite low compared to its revenue target of $350-370 million for its Amtagvi drug, the first and only cellular skin cancer treatment.
IOVA20.96%
post-image
post-image
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned